AZD6234 for Kidney Failure
Trial Summary
Will I have to stop taking my current medications?
The trial does not specify if you must stop all current medications, but if you are renally-impaired, you need to be on a stable dose of cardio-renal treatment for at least 2 weeks before screening. You must avoid certain medications like phosphate binders and some others within 10 hours before and after the study intervention.
What is the purpose of this trial?
This study will evaluate the pharmacokinetics (PK), safety, and tolerability of single subcutaneous dose of AZD6234 with end stage renal disease, severe, and possibly moderate and mild renal impairment in comparison to a matched healthy control group.
Research Team
Joel M Neutel, M.D.
Principal Investigator
Servico Integrado de Tecnicas Endovasculares
Kwabena Ayesu, M.D.
Principal Investigator
Servico Integrado de Tecnicas Endovasculares
Fadi Saba, M.D.
Principal Investigator
Servico Integrado de Tecnicas Endovasculares
Thomas C Marbury, M.D.
Principal Investigator
Servico Integrado de Tecnicas Endovasculares
Eligibility Criteria
This trial is for individuals with varying degrees of kidney impairment, including those on dialysis or with end-stage renal disease. Healthy participants are also included for comparison.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive a single subcutaneous dose of AZD6234 under fasted conditions
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- AZD6234
Find a Clinic Near You
Who Is Running the Clinical Trial?
AstraZeneca
Lead Sponsor
Sir Pascal Soriot
AstraZeneca
Chief Executive Officer since 2012
Veterinary Medicine from École nationale vétérinaire d'Alfort, MBA from HEC Paris
Dr. Cristian Massacesi
AstraZeneca
Chief Medical Officer since 2021
MD from Marche Polytechnic University, Oncology training at Royal Marsden Hospital, Kaplan Comprehensive Cancer Center, and European Institute of Oncology
Pascal Soriot
AstraZeneca
Chief Executive Officer since 2012
Veterinary Medicine from École nationale vétérinaire d'Alfort, MBA from HEC Paris
Cristian Massacesi
AstraZeneca
Chief Medical Officer since 2021
MD from Marche Polytechnic University, Medical Oncology training at Royal Marsden Hospital, Kaplan Comprehensive Cancer Center, and European Institute of Oncology